实验室值与肝硬化患者的隐性肝脑病之间的关联:一个多中心的回顾性研究
Kaori Koyano1, Masanori Atsukawa1, Akihito Tsubota2
1Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo 113-8602, Japan.
Journal of clinical medicine
|March 27, 2025
概括
低维生素D3和白蛋白水平,以及食道静脉,与肝硬化患者的隐性肝脑病 (CHE) 有关. 对于那些有这些风险因素的人来说,早期检测至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 神经学 神经学
- 临床诊断 临床诊断 临床诊断
背景情况:
- 在肝硬化患者中,越来越需要隐蔽肝脑病 (CHE) 诊断.
- 识别与CHE相关的新型因素对于临床实践至关重要.
研究的目的:
- 确定与肝硬化患者的隐性肝脑病变 (CHE) 相关的新型临床因素.
- 调查维生素D3,白蛋白和食道静脉与CHE的关联.
主要方法:
- 在17个机构对402名肝硬化患者进行了回顾性研究.
- 使用Stroop测试对CHE进行诊断.
- 多变量分析以确定独立的风险因素.
主要成果:
- 低25-氧维生素D3 (25(OH) D3) 和食道静脉 (EV) 是CHE的独立风险因素.
- 低的白蛋白和低的25 (((OH) D3是CHE的独立实验室因素.
- 最佳切割值:白蛋白 3.7 g/dL,25(OH) D3 16.5 ng/mL. 这是一个很好的标准. CHE的患病率在较低的25 ((OH) D3水平时增加.
结论:
- 低的25 (((OH) D3和白蛋白水平,以及EV与肝硬化中的CHE正面相关.
- 降低25~OH) D3水平与增加的CHE患病率相关.
- 患有这些风险因素的患者需要对CHE进行仔细检查.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


